L'intérêt à découvert pour MEDIROM Healthcare Techs donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de MEDIROM Healthcare Techs. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

MEDIROM Healthcare Techs (NASDAQ:MRM) Stock, Rapport sur les intérêts à découvert

MEDIROM Healthcare Techs

MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.

MEDIROM Healthcare Technologies Inc. - American Depositary Share

MEDIROM Healthcare Technologies Inc

MMA Offshore Ltd

MariMed Inc

MIRAMAR RESOURCES LTD by MIRAMAR RESOURCES LTD

Macro Economic Events

News

Economics

Federal Reserve

Fed's Bostic Says Changes In Supply Chains Means Business Cost Structures Will Also Change, Something Fed Will Need To Understand

Evercore ISI Group analyst Elizabeth Anderson maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Outperform and lowers the price target from $29 to $27.

Price Target

Analyst Ratings

XRAY

Evercore ISI Group Maintains Outperform on Dentsply Sirona, Lowers Price Target to $27

JPMorgan Chase &amp; Co.&#8216;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) J.P. Morgan Asset Management penned a deal to enhance its Morgan Money offering through a strategic partnership with GLMX,<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41229723/j-p-morgan-asset-management-enhances-morgan-money-with-expanded-access-to-diverse-asset-classes" rel="noreferrer noopener"> a global money market trading platform</a>.
Morgan Money is a global trading platform that provides effective short-term investment management solutions tailored for institutional investors.
With $313 billion in assets under management as of June 30, 2024, the platform facilitates efficient liquidity and cash investment management, allowing clients to maximize outcomes with fewer resources.
This collaboration allows clients to access GLMX&#8217;s advanced trading technology directly, broadening their short-term investment options.
The integration offers a comprehensive suite of money market instruments, including money market funds, repurchase agreements, time deposits, CDs, commercial paper, and government securities.
Glenn Havlicek, CEO and Co-founder of GLMX, said, &#8220;This collaboration with J.P. Morgan Asset Management is a result of investors&#8217; desire to access the entire investable universe of short-term instruments with a seamless experience.&#8221;
&#8220;We bring GLMX&#8217;s&nbsp;$3 trillion&nbsp;ecosystem to J.P. Morgan&#8217;s client base as we seek to collaborate with industry leaders to provide innovative and easily accessible solutions for our collective clients.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41185532/jp-morgan-takes-stake-in-australian-casino-operator-star-entertainment-details" rel="noreferrer noopener">JP Morgan Takes Stake In Australian Casino Operator Star Entertainment: Details</a>
Last week, J.P. Morgan expanded its Canadian business with the launch of two active ETFs <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41144035/j-p-morgan-launches-new-etfs-plans-to-add-jobs-in-canada" rel="noreferrer noopener">on the Toronto Stock Exchange</a>.
Investors can gain access to the stock via&nbsp;iShares U.S. Financial Services ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYG#NYSE">IYG</a>) and&nbsp;SPDR Select Sector Fund – Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>).
Price Action: JPM shares are down 0.07% at $210.78 at the last check Tuesday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41223849/pepsico-jpmorgan-and-wells-fargo-to-kick-off-earnings-season-as-investors-eye-s-p-5" target="_blank" rel="noreferrer noopener">PepsiCo, JPMorgan And Wells Fargo To Kick Off Earnings Season As Investors Eye S&amp;P 500 Near Record Highs: Interest Rates And Inflation In Focus</a></li>
</ul>

Equities

Large Cap

iShares Trust Dow Jones US Financial Services Index Fund

J.P. Morgan Teams Up With GLMX To Supercharge Short-Term Investment Options

Barclays analyst Terry Ma maintains First American Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FAF#NYSE">FAF</a>) with a Equal-Weight and raises the price target from $61 to $70.

Barclays Maintains Equal-Weight on First American Financial, Raises Price Target to $70

Barclays analyst Mark Devries maintains Fidelity National Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) with a Equal-Weight and raises the price target from $56 to $59.

Barclays Maintains Equal-Weight on Fidelity National Finl, Raises Price Target to $59

Evercore ISI Group analyst Elizabeth Anderson maintains Waystar Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAY#NASDAQ">WAY</a>) with a Outperform and raises the price target from $27 to $32.

Evercore ISI Group Maintains Outperform on Waystar Holding, Raises Price Target to $32

Macro Notification

General

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

Syrian Air Defences Intercept 'Hostile' Targets In Vicinity Of Syria's Damascus

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock&#39;s price. Do they really matter, though?
Let&#39;s take a look at what these Wall Street heavyweights have to say about ACM Research, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acmr#NASDAQ">ACMR</a>) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
ACM Research currently has an average brokerage recommendation of 1.25, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by six brokerage firms. An ABR of 1.25 approximates between Strong Buy and Buy.
Of the six recommendations that derive the current ABR, four are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 66.7% and 33.3% of all recommendations.
<h2>Brokerage Recommendation Trends for ACMR</h2>
<img alt="Broker Rating Breakdown Chart for ACMR" class="chart" src="https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/ACMR_10082024.png" style="width:100%" title="" /> 
While the ABR calls for buying ACM Research, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five &quot;Strong Buy&quot; recommendations for every &quot;Strong Sell&quot; recommendation.
In other words, their interests aren&#39;t always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock&#39;s price movement.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock&#39;s price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
<h2>ABR Should Not Be Confused With Zacks Rank</h2>
In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers&#39; vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.
There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
<h2>Should You Invest in ACMR?</h2>
Looking at the earnings estimate revisions for ACM Research, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $1.63.
Analysts&#39; steady views regarding the company&#39;s earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for ACM Research.
It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for ACM Research.
<a href="https://www.zacks.com/stock/news/2347429/acm-research-acmr-is-considered-a-good-investment-by-brokers-is-that-true?cid=CS-BENZ-FT-fundamental_analysis|average_broker_rating-2347429">To read this article on Zacks.com click here.</a>

Earnings

Small Cap

Markets

Trading Ideas

ACMR

ACM Research Is Considered a Good Investment by Brokers: Is That True?

<a href="https://www.benzinga.com/events/cannabis-conference/livestream/" title="https://www.benzinga.com/events/cannabis-conference/livestream/">https://www.benzinga.com/events/cannabis-conference/livestream/</a>

Cannabis

Events

Exclusives

MSOS

Zuanic & Associates Managing Partner Pablo Zuanic Says [M&A Strategy Changes From Buyer Perspective] If You Get Rescheduling You Get Some Optic Evaluations; MSOS Very Low Opportunities; MSOS Are Going To Germany To Conferences And Meeting People

Evercore ISI Group analyst Elizabeth Anderson maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a In-Line and raises the price target from $8 to $9.

TDOC

Evercore ISI Group Maintains In-Line on Teladoc Health, Raises Price Target to $9

Barclays analyst Terence Malone maintains Essent Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESNT#NYSE">ESNT</a>) with a Overweight and raises the price target from $64 to $72.

ESNT

Barclays Maintains Overweight on Essent Group, Raises Price Target to $72

Evercore ISI Group analyst Ross Muken maintains Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) with a In-Line and lowers the price target from $23 to $22.

PDCO

Evercore ISI Group Maintains In-Line on Patterson Cos, Lowers Price Target to $22

WIIM

SAP shares are trading higher after the company unveiled AI-powered innovative business tools to enhance productivity and data use at its SAP TechEd conference.

Barclays analyst Nicholas Campanella maintains Entergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) with a Overweight and lowers the price target from $138 to $137.

Barclays Maintains Overweight on Entergy, Lowers Price Target to $137

Streaming giant Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) could increase prices for ad-supported plans and the company&#8217;s standard plan to increase free cash flow, an analyst says ahead of the company&#8217;s <a href="https://www.benzinga.com/earnings">third-quarter financial results. </a>
The Netflix Analyst: JPMorgan analyst Doug Anmuth reiterated an Overweight rating on Netflix with a $750 price target in a new investor note.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41209970/netflix-analysts-turn-more-optimistic-ahead-of-earnings-expensive-for-a-reason">Netflix Analysts Turn More Optimistic Ahead Of Earnings: &#8216;Expensive For A Reason&#8217;</a>
The Analyst Takeaways: Potential price increases and an update on the ad-supported plan are catalysts for Netflix that Anmuth is watching in the upcoming third-quarter financial results.
"We remain positive on Netflix shares heading into third-quarter earnings on Thursday, Oct. 17, while recognizing elevated expectations," Anmuth said.
The analyst highlights Netflix stock is up 17% from August lows and up more than 40% year-to-date, as seen on the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100824&amp;t=be2bearmibe3na1">Benzinga Pro chart </a>below.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1001" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08123754/Screenshot-203.png" alt="" class="wp-image-586080" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08123754/Screenshot-203.png 1001w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08123754/Screenshot-203-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08123754/Screenshot-203-768x387.png 768w" sizes="(max-width: 1001px) 100vw, 1001px" /></a></figure>
Despite Netflix stock trading near all-time highs, Anmuth is bullish on several upcoming catalysts for the streaming company.
"We remain bullish on NFLX's ability to grow revenue in the mid-teens in 2024 &amp; 2025 and low double-digits in 2026, further expand margins and drive multi-year FCF growth."
The analyst said Netflix's ad-supported plan can continue to increase monetization efforts for the company in 2025 and beyond.
"While the Ad Tier is currently a drag on total company ARM (average revenue per member), we expect focus on ad formats, NFLX's in-house ad tech platform, and programmatic and measurement partnerships to drive higher monetization."
Netflix's basic plan ($11.99 per month) could make up around 15% of U.S. subscribers said Anmuth. With the plan being phased out, some users will have to shift to the ad-supported plan or up to the $15.49 per month standard plan.
The streaming giant could also raise the price of the standard plan or the ad-supported plan soon, according to Anmuth. The analyst notes the standard plan was last increased in January 2022.
Anmuth predicts Netflix had net adds of seven million in the third quarter, compared to most investors predicting six to seven million.
While engagement was high among users in the third quarter with shows and movies, Anmuth is already looking ahead.
"We believe the fourth-quarter content slate is strong."
The analyst highlights shows like "Outer Banks," "Lonely Planet" and "Squid Game," while also mentioning the live sports content that includes a boxing match between Jake Paul and Mike Tyson and two National Football League games on Christmas Day.
"We expect a bigger push into live sports over time, particularly as negotiating leverage shifts in NFLX's direction."
Anmuth said Netflix's ad-supported plan growth and a price increase will lead to higher free cash flow guidance by the company.
"We believe NFLX's global scale, strong engagement and diversified content will push NFLX toward becoming the default choice for how users consume TV, film &amp; other long-form content."
NFLX Price Action: Netflix stock is up 2.45% to $718.97 on Tuesday versus a 52-week trading range of $344.73 to $725.25.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41123711/netflix-stock-could-get-boost-from-nfl-games-squid-game-season-2-analyst-says-conte">Netflix Stock Could Get Boost From NFL Games, &#8216;Squid Game&#8217; Season 2: Analyst Says &#8216;Content Catalysts&#8217; Begin In Q4</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Entertainment

Reiteration

Sports

Media

NFLX

Netflix To Become 'Default Choice' For TV, Movies? Analyst Predicts More Live Sports, Price Increases

MGO Tax Partner Barbara Webb Says [ESOP] Are Attractive Because That S Corporation Does Not Pay Taxes; If S Corporation Owned By 100% ESOP, Income Flows Out To Tax-exempt Entity, Which So 280e Doesnt Have Impact

Alibaba Group Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) shares are trading lower on Tuesday, among other U.S. listed Chinese stocks, after China&#8217;s National Development and Reform Commission (NDRC) announced disappointing <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41227136/chinese-stocks-plunge-as-stimulus-hopes-fade-hong-kong-posts-worst-daily-decline-si">stimulus measures</a>.
What To Know: Investors anticipated the commission&#8217;s chairman Zheng Shanjie would release bold measures to boost the country&#8217;s economy during a press conference Tuesday. However, Zheng&#8217;s measures amounted to releasing a 100 billion yuan investment plan for 2025 by the end of this month and a separate 100 billion yuan for construction projects.
Following the underwhelming stimulus measures, China&#8217;s stock markets fell on Tuesday, cutting off gains. Hong Kong&#8217;s Hang Seng index closed 9.4% lower on Tuesday. In addition, the Shanghai Composite Index experienced significant fluctuations throughout the day, but despite the volatility, it ultimately closed with a 4.6% gain.
Alibaba and other U.S. listed Chinese stocks are heavily owned by foreign investors who may be quick to react to market shifts. Other U.S. listed Chinese stocks effected by this shift include JD.Com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) and NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>).
How To Buy Alibaba Shares
By now you're likely curious about how to participate in the market for Alibaba Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
See Also: <a href="https://www.benzinga.com/news/earnings/24/10/41224832/us-stocks-poised-to-bounce-back-as-bond-yields-dip-oil-prices-slide-pepsico-pulls-back-set-up-quite">US Stocks Poised To Bounce Back As Bond Yields Dip, Oil Prices Slide, PepsiCo Pulls Back: Set-up &#8216;Quite Positive&#8217; For Equities, Says Economist</a>
BABA Price Action: At the time of writing, Alibaba shares are trading 7.07% lower at $109.21, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo via Shutterstock

Movers

BABA

What's Going On With Alibaba Stock Tuesday?

Evercore ISI Group analyst Elizabeth Anderson maintains IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) with a Outperform and lowers the price target from $270 to $265.

Evercore ISI Group Maintains Outperform on IQVIA Hldgs, Lowers Price Target to $265

BofA Securities analyst Bryan D. Spillane expresses views on PepsiCo, Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) mixed third-quarter <a target="_blank" href="https://www.benzinga.com/quote/PEP/analyst-ratings" rel="noreferrer noopener">results reported on Tuesday</a>.
Today, the company reported adjusted EPS of $2.31, which&nbsp;beat the consensus estimate of $2.29, while revenue of $23.319 billion missed <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41225048/pepsico-adjusts-2024-revenue-expectations-after-mixed-q3-performance-and-global-challenges" rel="noreferrer noopener">the consensus estimate of $23.825 billion</a>.
For 2024, PepsiCo expects a low-single-digit increase in organic revenue (previously ~4%) and continues to expect at least an 8% increase in&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">core constant currency EPS.</a>
PepsiCo's assumption and guidance imply that 2024 adjusted EPS of at least $8.15 (consensus $8.15) will be a 7% increase year over year.
Spillane notes that the second half of the year typically accounts for over half of total revenue, and the guidance suggests organic growth of -1% to +3% in the fourth quarter.
The analyst writes that PEP is likely relying on higher productivity than initially planned to maintain its reiterated EPS, despite lowering its organic sales guidance.
However, the volume performance in the third quarter indicates a possible need for additional support next year, adds the analyst.
The analyst writes that with remedial actions addressing volume weakness now in place, he expects the stock to perform well if market share improves.
The analyst says that PEP&#8217;s premium valuation of 20x over non-alcoholic beverage peers is justified by its strengthened position and pricing power amid ongoing inflationary pressures.
The analyst maintains the <a href="https://www.benzinga.com/quote/PEP/analyst-ratings" target="_blank" rel="noreferrer noopener">Buy rating and $185 price target.</a>
Investors can gain exposure to the stock via&nbsp;iShares U.S. Consumer Staples ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYK#NYSE">IYK</a>) and First Trust Nasdaq Food &amp; Beverage ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXG#NASDAQ">FTXG</a>).
Price Action: PEP shares are up 0.89% at $168.69 at the last check Tuesday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41234471" target="_blank" rel="noreferrer noopener">September Inflation Preview: Traders Brace For Market Jitters As Crucial Report Looms Ahead Of Fed Meeting</a></li>
</ul>

FTXG

iShares Trust Dow Jones USnsumer Goods Sector Index Fund

PepsiCo's Higher Productivity Key To Navigating Slower Sales Growth, BofA Analyst Remains Bullish

Barclays analyst Lauren Lieberman maintains Duckhorn Portfolio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAPA#NYSE">NAPA</a>) with a Equal-Weight and raises the price target from $6 to $11.

NAPA

Barclays Maintains Equal-Weight on Duckhorn Portfolio, Raises Price Target to $11

Medirom Healthcare Technologies, Inc. (MRM) has released an update. Medirom Healthcare Technologies Inc. reported a marginal decrease in total cust...

Medirom Reports Growth in Customer Value Metrics

MEDIROM Healthcare Technologies (MRM) has released an update. MEDIROM Healthcare Technologies Inc., a holistic healthcare provider, has reported a ...

MEDIROM Reports May KPIs and User Growth

Medirom to buy majority stake in Japan Gene Medicine

MEDIROM Healthcare Technologies (MRM) has released an update. MEDIROM Healthcare Technologies Inc. is set to acquire a 70% stake in Japan Gene Medi...

MEDIROM Expands with Genetic Testing Firm Buyout

MEDIROM Healthcare Technologies (MRM) has released an update. MEDIROM Healthcare Technologies Inc. has reported an increase in total customers serv...

MEDIROM Reports Growth and Expanding User Base

MEDIROM Healthcare Technologies (MRM) has released an update. MEDIROM Healthcare Technologies Inc. has announced a capital and business alliance wi...

MEDIROM Forms Alliance with NFES, Boosts Series A Funding

Medirom Mother Labs and NFES Technologies form capital and business alliance

MEDIROM Healthcare Technologies (MRM) has released an update. MEDIROM Healthcare Technologies Inc. has disclosed its July 2024 performance, noting ...

MEDIROM Reports Key July 2024 Performance Metrics

MEDIROM Healthcare Technologies (MRM) has released an update. MEDIROM Healthcare Technologies Inc. reports a slight decrease in total customers ser...

Comments

MEDIROM Healthcare Techs

Intérêt court

MEDIROM Healthcare Techs (NASDAQ:MRM) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL